title: Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis.
abstract: Pancreatic cancer accounts for more than 250,000 deaths worldwide each year. Recent studies have shown that belinostat, a novel pan histone deacetylases inhibitor (HDACi) induces apoptosis and growth inhibition in pancreatic cancer cells. However, the underlying mechanisms are not fully understood. In the current study, we found that AMP-activated protein kinase (AMPK) activation was required for belinostat-induced apoptosis and anti-proliferation in PANC-1 pancreatic cancer cells. A significant AMPK activation was induced by belinostat in PANC-1 cells. Inhibition of AMPK by RNAi knockdown or dominant negative (DN) mutation significantly inhibited belinostat-induced apoptosis in PANC-1 cells. Reversely, AMPK activator AICAR and A-769662 exerted strong cytotoxicity in PANC-1 cells. Belinostat promoted reactive oxygen species (ROS) production in PANC-1 cells, increased ROS induced transforming growth factor-β-activating kinase 1 (TAK1)/AMPK association to activate AMPK. Meanwhile, anti-oxidants N-Acetyl-Cysteine (NAC) and MnTBAP as well as TAK1 shRNA knockdown suppressed belinostat-induced AMPK activation and PANC-1 cell apoptosis. In conclusion, we propose that belinostat-induced apoptosis and growth inhibition require the activation of ROS-TAK1-AMPK signaling axis in cultured pancreatic cancer cells.
authors.affiliation: Department of Abdominal Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China. wangbin69@yahoo.com
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.forename: Xin-bao
authors.initials: XB
authors.lastname: Wang
authors.forename: Li-yu
authors.initials: LY
authors.lastname: Chen
authors.forename: Ling
authors.initials: L
authors.lastname: Huang
authors.forename: Rui-zen
authors.initials: RZ
authors.lastname: Dong
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D020930:MAP Kinase Kinase Kinases / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000099151:MAP Kinase Kinase Kinase 7
chemical_list: D055372:AMP-Activated Protein Kinases; D006877:Hydroxamic Acids; D020930:MAP Kinase Kinase Kinases; D017382:Reactive Oxygen Species; D013449:Sulfonamides; D058570:TOR Serine-Threonine Kinases; D000099151:MAP Kinase Kinase Kinase 7; C546842:MTOR protein, human; C487081:belinostat
keywords: (mTOR); ACC; AMP-activated protein kinase; AMPK; Apoptosis; Belinostat; H(2)O(2); HDACi; N-acetyl-cysteine; NAC; Pancreatic cancer; ROS; TAK1; acetyl-CoA carboxylase; histone deacetylases inhibitor; hydrogen peroxide; mammalian target of rapamycin; reactive oxygen species; transforming growth factor-β-activating kinase 1